Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
+$0.18 today
- Market cap
- $1.71B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
Volume 0.71M
Average 0.84M
MAZE Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Maze Therapeutics, Inc.NASDAQ: MAZE
Retained Earnings · Q1 FY2026 · quarter ended Mar 2026
Retained earnings remains negative
Q1 FY2026 retained earnings was -$513.76M, compared with -$391.21M a year earlier.
Context
- Retained earnings amounted to 122.4% of total assets at the end of Q1 FY2026, up 4.9 pp from a year earlier.
- Retained earnings grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -31.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (489.55M) USD
- Year-over-year change
- -36.6%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (489.55M) | -36.6% |
| FY2024 | 2024-12-31 | (358.43M) | +9.4% |
| FY2023 | 2023-12-31 | (395.69M) | -34.0% |
| FY2022 | 2022-12-31 | (295.27M) | — |
Retained Earnings vs competitors
How MAZE compares with its peers on the latest reported figures
- Peers report in different currencies, so retained earnings is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -31.3% is the 5th highest of 8, against a peer median of -23.8%.
- Retained earnings amounts to 122.4% of total assets for MAZE, versus a peer median of 142.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | -$182.81M USD | -23.8% | — | 344.4% | |
SEPNSepterna, Inc. | Sep 2026 | -$215.51M USD | -37.7% | — | 34.8% |
| Dec 2025 | -€354.14M EUR | -92.2% | — | 142.3% | |
BIOABioAge Labs, Inc. | Mar 2026 | -$355.67M USD | -33.8% | — | 89.4% |
| Mar 2026 | -$513.76M USD | -31.3% | — | 122.4% | |
| Mar 2026 | -$984.54M USD | -6.3% | — | 195.1% | |
| Sep 2026 | -$1.6B USD | -8.2% | — | 188.3% | |
| Jun 2026 | -$2.88B USD | -1.3% | — | 88.7% | |
| Peer median (excluding MAZE) | — | -23.8% | — | 142.3% | |
Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Maze Therapeutics, Inc.
NASDAQ:MAZE
Intrinsic Alpha fair value
Locked
Current Price
$31.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.